Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2797 - Phase II study of S-1 and Oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Cytotoxic Therapy

Tumour Site

Gastric Cancer


Kazuma Kobayashi


Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282


K. Kobayashi1, M. Iwatsuki2, H. Orita3, S. Hidaka4, T. Arigami5, T. Kusumoto6, H. Satake7, E. Oki8, K. Satoshi9, K. Tobimatsu10, M. Shimokawa11, H. Saeki12, A. Makiyama13, Y. Kakeji14, S. Natsugoe15, H. Baba2, S. Eguchi1, Y. Maehara8

Author affiliations

  • 1 Department Of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 852-8501 - Nagasaki/JP
  • 2 Department Of Gastroenterological Surgery, Graduate School Of Medical Sciences, Kumamoto University, Kumamoto/JP
  • 3 Department Of Surgery, NAKATSU MUNICIPAL HOSPITAL, Nakatsu/JP
  • 4 Division Of Surgical oncology,department Of Translational Medical Sciences, Graduate school of biomedical sciences, Nagasaki University, Nagasaki/JP
  • 5 Kagoshima University, Department of Onco-biological Surgery,, Kagoshima/JP
  • 6 Department Of Gastroenterological Surgery / Clinical research Institute Cancer Research Division, National Kyushu Medical Center, Fukuoka/JP
  • 7 Department Of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 8 Department Of Surgery And Science, Graduate School Of Medical Sciences, Kyushu University, Fukuoka/JP
  • 9 Department Of Surgery, Oita prefectural Hospital, Oita/JP
  • 10 Division Of Gastroenterology, Department Of Internal Medicine, Kobe University Graduate School of Medicine, Kobe/JP
  • 11 Clinical research Institute, Cancer Biostatistics Laboratory, National Kyushu Cancer Center, 811-1395 - FUKUOKA/JP
  • 12 Department Of Surgery And Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka/JP
  • 13 Department Of Hematology/oncology, Japan Community Healthcare Organization Kyushu Hospital, FUKUOKA/JP
  • 14 Division Of Gastrointestinal Surgery,department Of Surgery, Graduate School of Medicine, Kobe University, Kobe/JP
  • 15 Department Of Digestive Surgery,breast And Thyroid Surgery, Kagoshima University, Kagoshima/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2797


Neoadjuvant chemotherapy is an accepted treatment method to improve the survival for advanced gastric cancer in worldwide. This phase II study, KSCC1601, aimed to investigate efficacy and safety of S-1 and Oxaliplatin for locally advanced gastric (LAGC) and esophago-gastric cancer (EGC).


Patients received oral S-1 40-60 mg twice daily on days 1 to 14 every 3 weeks plus intravenous oxaliplatin 130 mg/m2 on day 1 every 3 weeks for 3 courses, followed by gastrectomy with D2 lymphadenectomy. The primary endpoint was pathological response rate (pRR) according to the proportion of necrosis in the tumor: grade 0, no necrosis; grade 1a, < 1/3 necrosis; grade 1b, > 1/3 or < 2/3 necrosis; grade 2, > 2/3 or < all necrosis; and grade 3, all parts of the tumors affected by necrosis. A sample size of 46 was set according to one-sided significance level of 0.05 and power of 80% based on an exact binomial distribution, and assuming the null hypothesis of a 30% pRR and an alternative hypothesis of a 50% pRR. The incidence of anastomosis leakage in EGC was the main secondary endpoint. Other secondary endpoints were R0 resection rate, overall survival, relapse free survival and safety.


Between 2016 April and 2017 July, 47 patients (24 EGC, 23 LAGC) were enrolled in this study. All patients were eligible for analysis. 42 patients (89.4%:95%CI 76.9-96.5) underwent surgery, and curative resection was performed in 41 patients. The rate of protocol treatment completeness was 42 patients (89.4%:95%CI 76.9-96.5%). pRR, the primary endpoint (grade 1b to 3), was 25 cases (59.5%:90%CI 45.7-72.3%) of primary lesions. The main toxicities of neoadjuvant chemotherapy were grade 3/4 thrombocytopenia (10.6%), neutropenia (6.4%), anemia (4.3%), grade 3/4 anorexia (12.8%). The number of anastomosis leakage so as to 20 EGC according to the Clavien–Dindo classification was 2 for grade IIIa, 2 for grade IIIb, and 1 for grade IV (25.0%:90%CI 10.4-45.6%). Survival data will be updated in further investigation.


The S-1 and oxaliplatin was well tolerated and is promising as a preoperative chemotherapy regimen for patients with LAGC and EGC.

Clinical trial identification


Legal entity responsible for the study



Yakult Honsha Co., Ltd., Cres Kyushu.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.